{"id":"W4402543961","doi":"10.1016/s0140-6736(24)01756-2","title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; Genentech; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Seagen; Incyte; BeiGene; Regeneron Pharmaceuticals; National Institutes of Health; Helsinn; Merck KGaA; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Chemotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Adjuvant; Neoadjuvant therapy; Placebo; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001060047,0.001154626,0.003437875,0.0003693429,0.0002645118,0.0003516096,0.0007876499,0.0003275452,0.0006852595],"category_scores_gemma":[0.00001342384,0.0006651268,0.0005729087,0.001018845,0.0003441226,0.0002792021,0.00006015766,0.001110745,0.00002128378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008978239,"about_ca_system_score_gemma":0.001166284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00240637,"about_ca_topic_score_gemma":0.0006525022,"domain_scores_codex":[0.9945033,0.0002552447,0.00129407,0.001279744,0.001196912,0.001470767],"domain_scores_gemma":[0.9971208,0.000320184,0.0005482009,0.001479393,0.000202407,0.0003290153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9720874,0.001548428,0.002313079,0.0004057299,0.002325994,0.0001690589,0.003501176,0.0001986463,0.003097383,0.000004879091,0.01046833,0.00387985],"study_design_scores_gemma":[0.9739466,0.004439432,0.001636125,0.001329757,0.0008800133,0.00002457869,0.0001796376,0.006547946,0.002673332,0.000003312627,0.007358652,0.0009805729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9685688,0.008112867,0.000498944,0.00340598,0.0007053925,0.01695855,0.0003271058,0.0003077595,0.001114595],"genre_scores_gemma":[0.987525,0.001940999,0.0001711343,0.002051534,0.001102291,0.002946447,0.0003134514,0.0003072786,0.003641797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01895626,"threshold_uncertainty_score":0.99958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01784361033734386,"score_gpt":0.2925656126716955,"score_spread":0.2747220023343516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}